Tolerance Bio

Executive Summary

Tolerance Bio is a preclinical-stage biotechnology company pioneering a novel approach to immune-mediated diseases by preserving and restoring thymus function. The thymus is the master regulator of immune tolerance, and its decline with age or disease underlies numerous conditions including autoimmunity, transplant rejection, infections, and cancer. The company's platform aims to rejuvenate thymic activity, potentially enabling durable immune tolerance and addressing large unmet medical needs. Founded in 2019 and based in San Diego, Tolerance Bio is privately held with limited public information. While still in early development, the science is conceptually compelling and could represent a paradigm shift if successful. The company faces typical early-stage risks including technical validation, manufacturing challenges, and financing needs. Overall, Tolerance Bio is a high-risk, high-reward opportunity in cell and gene therapy.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate IND filing20% success
• Q3 2026Preclinical proof-of-concept data publication40% success